Dr. Lisa Ford | Clinical Research | Best Researcher Award
Executive Medical Director at Johnson and Johnson | United States
Dr. Lisa Melanie Ford, M.D., FAAN, stands as a distinguished physician, academician, and research leader whose career reflects an enduring dedication to advancing pediatric neurology and neuroscience innovation. Trained at Temple University School of Medicine and the Children’s Hospital Medical Center in Cincinnati, she cultivated deep expertise in child neurology, neonatology, and neurodevelopmental disorders. Her career bridges academic excellence and industry leadership, having served as Clinical Associate Professor of Neurosciences and Pediatrics at Rutgers University, while also directing and leading transformative clinical research initiatives at major pharmaceutical organizations including CIBA-GEIGY, Whitehall-Robins Healthcare, and Janssen Pharmaceuticals. Renowned for her contributions to the understanding and treatment of neurological and psychiatric disorders, Dr. Ford’s work has influenced both clinical practices and drug development strategies in pediatric and adult neurology. Her leadership at Janssen Neuroscience, where she serves as Senior Director of Research and Development and Clinical Development Team Leader, exemplifies her commitment to innovation, evidence-based medicine, and patient-centered care. Recognized by numerous national and international honors, Dr. Ford’s achievements include accolades from the American Academy of Neurology, Johnson & Johnson, and the Consumers Research Council of America, celebrating her as one of the nation’s top physicians. A Fellow of the American Academy of Neurology and the American Epilepsy Society, Dr. Ford continues to be a guiding force in translating scientific discovery into therapeutic progress. Her legacy reflects an inspiring blend of medical excellence, visionary leadership, and lifelong dedication to improving neurological health across generations.
Featured Publications:
Authors not listed. (2025). A randomized, double-blind, placebo-controlled, time-to-event study of the efficacy and safety of JNJ-40411813 in combination with levetiracetam or brivaracetam in patients with focal onset seizures. Epilepsia.
Authors not listed. (2025). Brain MRI signatures across sex and CSF Alzheimer’s disease biomarkers. Brain Communications.
Authors not listed. (2024). Amyloid-PET imaging predicts functional decline in clinically normal individuals. Alzheimer’s Research & Therapy.